---
title: "UBX.US (UBX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/UBX.US/news.md"
symbol: "UBX.US"
name: "UBX.US"
parent: "https://longbridge.com/en/quote/UBX.US.md"
datetime: "2026-03-14T09:00:01.347Z"
locales:
  - [en](https://longbridge.com/en/quote/UBX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/UBX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/UBX.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/UBX.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/UBX.US/news.md)


# UBX.US (UBX.US) — Related News

### [Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy](https://longbridge.com/en/news/279043374.md)
*2026-03-13T12:07:17.000Z*
> In Shanghai on March 13, 2026, Unixell Biotech marked a major achievement when UX-GIP001, its iPSC-derived allogeneic ce

### [](https://longbridge.com/en/news/276705610.md)
*2026-02-24T08:42:48.000Z*
> Novo Nordisk: UBT251 is jointly developed by Unity Biotechnology, a subsidiary of Turing Bioscience, and Novo Nordisk

### [Unity Biotechnology Files Dissolution Certificate Amid Cost-Cutting](https://longbridge.com/en/news/259125404.md)
*2025-09-26T21:29:34.000Z*
> Unity Biotechnology has filed a dissolution certificate as part of its cost-cutting strategy following the ASPIRE study 

### [Unity Biotechnology Approves Company Liquidation Plan](https://longbridge.com/en/news/258149914.md)
*2025-09-19T21:18:25.000Z*
> Unity Biotechnology has approved a liquidation plan following a special stockholder meeting on September 18, 2025. Stock